• Activity INFORMATION

  Overview

  In a podcast-style discussion, Mike Corvino, PharmD, and Cole Swanson, PharmD discuss newly FDA-approved medications in 2023 and the first part of 2024. New medications have been approved for many disease states including fatty liver disease, pulmonary hypertension, ulcerative colitis, and more. It is important that pharmacists and nurses be aware of these new medications when they encounter patients taking them. Being familiar with them will help identify drug interactions, side effects, and therapeutic appropriateness. This session seeks to explore these topics, focusing on how this information may change daily medical practice.

  Access the original podcast here.

  
  

  Handouts

  Financial Support By

  PharmCon

• Learning OBJECTIVES

  Pharmacist

  Identify relevant novel drugs approved in 2023 and early 2024

  Cite relevant clinical trials that led to the approval of these new drugs

  Recognize the place in therapy of these novel drugs and how they may change clinical practice

  Identify important background information and counseling points related to these medications

  Nurse

  Identify important background information and counseling points related to these medications

  Cite relevant clinical trials that led to the approval of these new drugs

  Identify relevant novel drugs approved in 2023 and early 2024

  Recognize the place in therapy of these novel drugs and how they may change clinical practice

• Activity ACCREDITATION

  Activity Type

  Knowledge

  CE Broker

  20-1204886

  Universal Activity Number

  Pharmacist 0798-0000-24-129-H01-P
  Nurse 0798-0000-24-129-H01-N
  

  PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

  PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

  In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

• Activity INSTRUCTION

  Faculty

  Coleman  Swanson, PharmD, CDCES Clinical Pharmacist - Neurology, MUSC Specialty Pharmacy Department

  Michael  Corvino, PharmD, BCPS, BCACP, CDCES Clinical Pharmacist, Fetter Health Care Network

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).